Clinical Trial Update: Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of an orally administered anti-CD3 monoclonal antibody in patients with nonalcoholic steatohepatitis (metabol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Oral anti-CD3 monoclonal antibody (anti-CD3 monoclonal antibody)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED